Jennifer Walden-Fain, MD
Internal Medicine · Prospect, KYNPI 1841211174
Payments from drug & device makers
Across 678 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$1K
- Novo Nordisk$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Pfizer$830
- AstraZeneca$598
- plus $4K from 33 others
What the payments were for
- Food & beverage$10,630100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 91 | $1,489 |
| Amgen | 77 | $1,335 |
| Novo Nordisk | 86 | $1,253 |
| Takeda Pharmaceuticals U.S.A., Inc. | 68 | $1,069 |
| Pfizer | 61 | $830 |
| AstraZeneca | 34 | $598 |
| Lilly USA, LLC | 41 | $556 |
| Esperion Therapeutics, Inc. | 37 | $537 |
| GSK | 33 | $465 |
| Novartis | 28 | $428 |
| Sanofi-aventis U.S. LLC | 13 | $190 |
| Vanda Pharmaceuticals Inc. | 9 | $186 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $177 |
| Axsome Therapeutics, Inc. | 7 | $150 |
| Phathom Pharmaceuticals, Inc. | 7 | $142 |
| Boehringer Ingelheim | 9 | $139 |
| Astellas Pharma US Inc | 7 | $116 |
| Eisai Inc. | 6 | $93 |
| Medtronic(2 entities) | 4 | $86 |
| Currax Pharmaceuticals LLC | 6 | $80 |
| Sanofi Pasteur Inc. | 5 | $76 |
| Exact Sciences | 4 | $65 |
| Abbott | 4 | $59 |
| Merck | 3 | $58 |
| Inspire Medical Systems, Inc. | 3 | $56 |
| Biohaven Pharmaceuticals, Inc. | 3 | $55 |
| Johnson & Johnson | 3 | $48 |
| Kowa Pharmaceuticals America, Inc. | 3 | $48 |
| Endo Pharmaceuticals Inc. | 3 | $45 |
| Seqirus USA Inc | 2 | $39 |
| Genentech USA, Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Averitas Pharma Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Bayer | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,645 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $99,268 |
| MounjaroTirzepatide | 57 | $57,784 |
| OzempicSemaglutide | 43 | $44,831 |
| JardianceEmpagliflozin | 31 | $42,168 |
| JanuviaSitagliptin Phosphate | 32 | $35,842 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $33,660 |
| Repatha SureclickEvolocumab | 41 | $29,935 |
| FarxigaDapagliflozin Propanediol | 18 | $27,324 |
| TrulicityDulaglutide | 13 | $26,141 |
| MyrbetriqMirabegron | 18 | $24,559 |
| TrintellixVortioxetine Hydrobromide | 13 | $16,270 |
| QuliptaAtogepant | 12 | $12,328 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $10,749 |
| Rosuvastatin Calcium | 513 | $6,170 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 85 | $3,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $830 | $100,69792 claims |
| Lilly USA, LLCMounjaro, Trulicity | $556 | $83,92570 claims |
| MerckJanuvia, Janumet | $58 | $46,59143 claims |
| Novo NordiskOzempic | $1,253 | $44,83143 claims |
| Boehringer IngelheimJardiance | $139 | $42,16831 claims |
| GSKTrelegy Ellipta | $465 | $33,66046 claims |
| AstraZenecaFarxiga | $598 | $27,32418 claims |
| Astellas Pharma US IncMyrbetriq | $116 | $24,55918 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,069 | $16,27013 claims |
| AbbVieQulipta, Synthroid | $1,489 | $15,20480 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Prospect
- Tina YuanProspect$15K
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.